The global health effort to eradicate poliomyelitis (polio) has encountered a number of unforeseen and unpredictable challenges. This article provides a timely review of progress made toward eradication, including the polio vaccines in use, and explores the reasons for delays in eradication target dates. It provides an overview of some of the remaining barriers to eradication and looks toward overcoming these through the Polio Eradication and Endgame Strategic Plan.
INTRODUCTION
The global health effort to eradicate poliomyelitis (polio) has encountered a number of unforeseen and unpredictable challenges which have been well documented [1] . This article provides a timely review of these challenges and looks toward overcoming the remaining barriers to eradication. the body through the mouth, multiplies in the oropharynx and the small intestine and exits in the feces from which it can spread rapidly through a community, especially in areas with poor hygiene and sanitation. The virus invades the local lymphoid tissues in the gastrointestinal tract, and may then enter the bloodstream and spread to the central nervous system. The virus may also spread to the central nervous system along the peripheral nerves. Over 90% of people infected with poliovirus have either no or very mild symptoms, which can easily go unrecognized [2] . This makes it very difficult to identify an outbreak immediately as asymptomatic infections can spread the infection 'silently' to others before the first case of polio paralysis is detected.
Therefore, herd immunity must be attained to prevent transmission and outbreaks of polio occurring.
Before the twentieth century, poor hygiene and sanitation meant that almost all children were exposed to poliovirus during infancy, which enabled natural immunity to build up in populations. The industrial revolution brought great sanitary improvements, including the separation of sewage from drinking water. While this proved vital in increasing public health standards in general, it initially had disastrous effects in relation to polio cases. It reduced childhood exposure to the virus and lowered immunity levels in communities, creating the perfect setting for epidemics to ignite [3] .
By the late 1980s, polio had been eliminated from most industrialized countries by routine immunization programs. However, it was estimated that polio still paralyzed more than 1,000 children every day globally, and that the poliovirus was circulating in more than 125 lesser developed countries [4] . Building on the global health success of the eradication of [5] . The Global Polio Eradication Initiative (GPEI) was formed to achieve this target, led by WHO, the United Nations Children's Fund, Rotary International, and the United States Centers for Disease Control and Prevention [6] .
The GPEI understood that increasing population immunity by routine vaccination supplemented by national mass immunization campaigns, and enhancing the epidemiological surveillance of the disease so that outbreaks could be rapidly detected and contained, would be the key to interrupting the transmission of wild poliovirus and achieving eradication [6] .
The vaccine most used globally is the trivalent oral polio vaccine (tOPV or 'Sabin vaccine'), which is effective against all three types of wild poliovirus. Use of tOPV can result in the 'passive' immunization of people living in areas of poor hygiene and sanitation who have not been directly vaccinated, as the virus continues to be excreted through the feces into the environment for several weeks after vaccination. A further advantage to its use is its cost, estimated to be between 11 and 14 US cents per dose [7] . There are also two more oral polio vaccines in use today: the monovalent vaccine (mOPV) and the bivalent vaccine (bOPV). In children being immunized for the first time, the monovalent vaccine (mOPV), consisting of just one type of the live attenuated strains of poliovirus, provides a greater immunity to the specific type of poliovirus being targeted and also provides increased immunity for the same number of doses compared with tOPV. This may be because there is no competition from the other two virus types in the vaccine [8] . The bivalent vaccine (bOPV) consists of live attenuated strains of both type-1 and type-3 poliovirus and improves the efficiency and impact of vaccination campaigns in areas where both types of poliovirus co-circulate. It is more effective than tOPV and almost as effective as mOPV in achieving protection [9] .
Unfortunately, in very rare cases, (approximately 1 in every 2.7 million first doses of the vaccine), the oral polio vaccines can cause a condition known as vaccineassociated paralytic polio [7] . Even more concerning is the potential for the live attenuated strains of the vaccine viruses to revert and re-acquire neurovirulence, resulting in circulating vaccine-derived polioviruses (cVDPVs) [10] . cVDPVs could pose a threat in a post-eradication world, with the ability to cause devastating outbreaks of polio at a time when immunity levels are reduced.
In most high-income countries, where the risk of polio infection is low, the inactivated polio vaccine (IPV or 'Salk vaccine') is used. IPV consists of ''killed'' strains of all three polioviruses, which is delivered via an injection. As it is not a ''live'' vaccine, IPV poses no risk to the recipient of vaccineassociated paralytic polio, nor is there any possibility of cVDPVs emerging [11] . However, it does need to be administered by a trained health worker, induces very low levels of immunity in the intestine and is over five times more expensive than the oral polio vaccine [11] .
Following its launch in 1988, the GPEI had a promising start and the Americas was the first India's greatest challenge to eradication was the sub-optimal effectiveness of tOPV in areas of high birth rates, poor sanitation as well as dense and migratory communities. This was particularly apparent in northern India and was only overcome by a substantial effort to push coverage rates to over 95% in particularly vulnerable populations and areas, and the
careful and tactical use of mOPV and bOPV [1] .
India was finally removed from the WHO list of polio-endemic countries in early 2012; an enormous achievement, considering that in 2009, India had the highest number of polio cases in the world [18] . It is expected that India will be officially certified as polio-free in 2014 [19] . The nature of poliovirus has posed its own challenge to eradication. Every child needs to be vaccinated multiple times to ensure full immunity, depending on the vaccine used [20] . This provides a significant logistical challenge to vaccinators, especially with migratory, displaced or hard to access populations. It can be very difficult to ascertain when and how many doses of vaccine each child has received and how many children were missed on vaccination days [1] .
This can pose a high risk to immunity levels as the virus may be transmitted over large distances with little warning. Natural disasters such as floods, earthquakes, hurricanes and tsunamis can also contribute to delays in eradication efforts. These can all have a detrimental impact on communications and road and health infrastructures, in some cases making it impossible to reach people except by air. Hospitals, medical centers and cold chain storage facilities can be damaged or destroyed and local health workers displaced.
The re-importation of wild poliovirus to countries that were previously polio-free has also complicated efforts. Angola, Chad and the Financing of the eradication effort remains a huge challenge. In the first quarter of 2012, GPEI activities were scaled down in 24 high-risk countries because of an acute funding shortage [31] . The budget for the Plan is US $5.5 billion, with a peak spending in 2013, then estimated to decline annually [32] . As of June 1, 2013, the GPEI was tracking over US$ 217 million in firm prospects, which if fully operationalized could close the 2013 funding gap, provided enough unspecified funds are secured to cover all cost categories [32] . However, pledges are very different to signed agreements and cash disbursements, and there is still a US $1.5 billion funding gap to fully resource the Plan. This shortfall has the potential to hamper the goal of eradication.
Today, eradication efforts continue. In 2012, 223 wild poliovirus cases were reported globally, more than a 60% decline compared with 2011 and only 5 countries reported cases in 2012 compared with 16 in 2011 [33] . As of August 13, 2013 , 181 wild poliovirus cases had already been reported [33] .
CONCLUSION
The global health effort to eradicate polio has faced numerous challenges since the launch of the GPEI. It is hoped that the last remaining obstacles have been identified and will be overcome within the established timeframe of the Polio Eradication and Endgame Strategic Plan. Crucially, success in the polio endgame would provide a strong evidence base and encourage political commitment to other such eradication initiatives. However, building on the lessons learned from the polio experience, any eventual strategy for measles eradication should strengthen routine immunization and not merely become a substitute [34] .
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